Suppr超能文献

修复脊髓损伤的药理学方法。

Pharmacological approaches to repair the injured spinal cord.

作者信息

Baptiste Darryl C, Fehlings Michael G

机构信息

Division of Cell and Molecular Biology, Toronto Western Research Institute and Krembil Neuroscience Centre, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.

出版信息

J Neurotrauma. 2006 Mar-Apr;23(3-4):318-34. doi: 10.1089/neu.2006.23.318.

Abstract

Acute traumatic spinal cord injury (SCI) results in a devastating loss of neurological function below the level of injury and adversely affects multiple systems within the body. The pathobiology of SCI involves a primary mechanical insult to the spinal cord and activation of a delayed secondary cascade of events, which ultimately causes progressive degeneration of the spinal cord. Whereas cell death from the mechanical injury is predominated by necrosis, secondary injury events trigger a continuum of necrotic and apoptotic cell death mechanisms. These secondary events include vascular abnormalities, ischemia-reperfusion, glutamate excitotoxicity and disturbances in ionic homeostasis, oxidative cell injury, and a robust inflammatory response. No gold standard therapy for SCI has been established, although clinical trials with methylprednisolone (NASCIS II and III) and GM-1 ganglioside (Maryland and Sygen) have demonstrated modest, albeit potentially important therapeutic benefits. In light of the overwhelming impact of SCI on the individual, other therapeutic interventions are urgently needed. A number of promising pharmacological therapies are currently under investigation for neuroprotective abilities in animal models of SCI. These include the sodium (Na+) channel blocker riluzole, the tetracycline derivative minocycline, the fusogen copolymer polyethylene glycol (PEG), and the tissue-protective hormone erythropoietin (EPO). Moreover, clinical trials investigating the putative neuroprotective and neuroregenerative properties ascribed to the Rho pathway antagonist, Cethrin (BioAxone Therapeutic, Inc.), and implantation of activated autologous macrophages (ProCord; Proneuron Biotechnologies) in patients with thoracic and cervical SCI are now underway. We anticipate that these studies will harken an era of renewed interest in translational clinical trials. Ultimately, due to the multi-factorial pathophysiology of traumatic SCI, effective therapies will require combined approaches.

摘要

急性创伤性脊髓损伤(SCI)会导致损伤平面以下神经功能严重丧失,并对体内多个系统产生不利影响。SCI的病理生物学涉及脊髓的原发性机械损伤以及延迟性继发性事件级联反应的激活,最终导致脊髓进行性退变。机械损伤导致的细胞死亡以坏死为主,而继发性损伤事件会引发一系列坏死和凋亡性细胞死亡机制。这些继发性事件包括血管异常、缺血再灌注、谷氨酸兴奋性毒性以及离子稳态紊乱、氧化细胞损伤和强烈的炎症反应。尽管甲基泼尼松龙(NASCIS II和III)和GM-1神经节苷脂(Maryland和Sygen)的临床试验已显示出适度的、尽管可能很重要的治疗益处,但尚未确立治疗SCI的金标准疗法。鉴于SCI对个体的巨大影响,迫切需要其他治疗干预措施。目前正在研究一些有前景的药物疗法在SCI动物模型中的神经保护能力。这些药物包括钠(Na+)通道阻滞剂利鲁唑、四环素衍生物米诺环素、融合剂共聚物聚乙二醇(PEG)以及组织保护激素促红细胞生成素(EPO)。此外,研究Rho通路拮抗剂Cethrin(BioAxone Therapeutic公司)的假定神经保护和神经再生特性以及在胸段和颈段SCI患者中植入活化自体巨噬细胞(ProCord;Proneuron Biotechnologies)的临床试验正在进行中。我们预计这些研究将开启对转化临床试验重新产生兴趣的时代。最终,由于创伤性SCI的多因素病理生理学,有效的治疗将需要综合方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验